Skip to main content
SpringerLink
Log in

Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia

  • Published:
Acta Biologica Hungarica Aims and scope Submit manuscript

Abstract

Thirty patients were investigated with hyperlipoproteinaemia, 15 patients with non-insulin dependent diabetes mellitus (NIDDM) and 15 with primary hyperlipoproteinaemia. The patients took 250 mg acipimox (5-metyl-pyrazine-carboxylic acid 4-oxide) 3 times per day for 2 months. Serum examinations were performed before and after 1 and 2 months of acipimox administration. After treatment the cholesterol and triglyceride levels decreased in both groups. Patients with NIDDM had 11% increase of high density lipoprotein-cholesterol (HDL-C) level at the end of the first, and 18% increase at the end of the second month, while patients with primary hyperlipoproteinaemia did not change significantly. The low density lipoprotein (LDL) level did not change significantly in either groups of patients. The apolipoprotein A 1 (apo A 1) levels increased significantly during the second month of acipimox administration. Uric acid levels decreased in both groups, but significant change could be detected mainly in the NIDDM group. Serum glucose level did not change in the non-diabetic patients, while it decreased significantly in the NIDDM group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beck-Nielsen, H. (1990) Molecular basis for the Randle hypothesis in patients with non-insulin dependent diabetes mellitus. Clinician 8, 9–11.

    Google Scholar 

  2. Berrish, T. S., Elliott, C., Cooper, B. G., Reed, J. W., Oroskov, H., Alberti, K. G., Walker, M. (1993) The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus. Diabetic Medicine 10, 152–158.

    Article  CAS  Google Scholar 

  3. Carlson, L. A., Olsson, A. G., Ballantyne, D. (1977) On the rise in LDL and HDL in response to the treatment of hypertrigliceridaemia in Type IV and Type V hyperlipoproteinaemias. Atherosclerosis 26, 603–609.

    Article  CAS  Google Scholar 

  4. Carlson, L. A. (1990) A focus on nicotinic acid. Clinician 8, 27.

    Google Scholar 

  5. Franceschini, G., Bernini, F., Michelagnoli, S., Bellosta, S., Vaccarino, V., Fumagalli, R., Sirtori, C. R. (1990) Lipoprotein changes and increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridaemia. Atherosclerosis 81, 41–49.

    Article  CAS  Google Scholar 

  6. Friedewald, W. T., Levy, R. I., Fredrickson, D. S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin. Chem. 17, 499.

    Google Scholar 

  7. Fuccella, L. M., Goldaniga, G., Lovisolo, P. P., Maggi, E., Musatti, L., Mandelli, V., Sirtori, S. R. (1980) Inhibition of lipolysis by nicotinic acid and by acipimox. Clin. Pharmacol. Therap. 28, 790.

    Article  CAS  Google Scholar 

  8. Fulcher, G. R., Catalano, C., Walker, M., Farrer, M., Thow, J., Whately-Smith, C. R., Alberti, K. G. (1992) A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non obese patients with type 2 diabetes mellitus. Diabetic Medicine 9, 908–914.

    Article  CAS  Google Scholar 

  9. Griffin, B. A., Caslake, M. J., Yip, B. (1990) Rapid isolation of discrete LDL subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 83, 59–67.

    Article  CAS  Google Scholar 

  10. Jacotot, B. (1990) Pharmacological intervention — The use of lipid lowering agents. Clinician. 8, 21.

    Google Scholar 

  11. Kissebah, A. H., Schectman, G. (1987) Hormones and lipoprotein metabolism. In: Shepherd, J. (ed.) Bailliere’s Clinical Endocrinology and Metabolism. — International Practice and Research. Baillieré Tindall, London, pp. 699–725.

    Google Scholar 

  12. Koev, D., Zlateva, S., Susic, M., Babic, D., Profozic, V., Skrabolo, Z., Langrova, H., Cvrkalova, A. L., Rajecova, E., Klimes, I. (1993) Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial. Diabetes Care 16, 1285–1290.

    Article  CAS  Google Scholar 

  13. Levy, R. I., Leager, T. (1972) Hypolipidemic drugs and lipoprotein metabolism. Adv. Exp. Med. Biol. 26, 155–163.

    Article  CAS  Google Scholar 

  14. Patsch, J. R., Karlin, J. B., Scott, L. W., Smith, L. C., Gotto, A. M. Jr. (1983) Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc. Natl. Acad. Sci. USA 80, 1449–1453.

    Article  CAS  Google Scholar 

  15. Patsch, J. R., Prasad, S., Gotto, A. M. Jr., Patsch, W. (1987) High density lipoprotein 2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia and to the activities of lipoprotein lipase and hepatic lipase. Clin. Invest. 80, 341–347.

    Article  CAS  Google Scholar 

  16. Pontiroli, A. E., Fattor, B., Pozza, G., Pianezzola, E., Benedetti, M. S., Musatti, L. (1992) Acipimox-induced facial skin flush: frequency, thermographic evaluation and relationship to plasma acipimox level. Eur. J. Clin. Pharmacol. 43, 145–148.

    Article  CAS  Google Scholar 

  17. Randle, P. J., Hales, C. N., Gariand, P. B., Newshome, E. A. (1963) The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolis disturbances of diabetes mellitus. Lancet i, 785–789.

    Article  Google Scholar 

  18. Regal, H., Lageder, H., Insigler, K., Maggi, E., Mandell, K., Tamassia, V., Petrescu, D. (1984) Effect of single oral dose of acipimox on glucose utilization after intravenous glucose load in obese patients. Drugs Exp. Clin. Rex. 10, 621.

    Google Scholar 

  19. Saloranta, C., Groop, L., Ekstrand, A., Fransilla-Kallunki, A., Eriksson, J., Taskinen, M. R. (1993) Different acut and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes. Diabetic Medicine 10, 950–957.

    Article  CAS  Google Scholar 

  20. Saloranta, C., Groop, L., Ekstrand, A., Fransilla-Kallunki, A., Taskinen, M. R. (1994) The effect of on antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients. Acta Diabetol. 31, 6–13.

    Article  CAS  Google Scholar 

  21. Shepherd, J. (1990) The action of nicotinic acid and its analogues on lipoprotein metabolism. Clinician 8, 27–32.

    Google Scholar 

  22. Tzanatos, H., Kontsikos, D., Agroyannis, B., Kepetanaki, A., Tsoutsos, D., Konstadinidou, I., Chondros, K., Exarchos, D. (1994) Lipid-lowering effect and safety of acipimox in hemodialysis patients and renal transplant recipients. Ren. Fail. 16, 391–405.

    Article  CAS  Google Scholar 

  23. Vaag, A., Skott, P., Oamsbo, P., Gall, M. A., Richter, E. A., Beck-Nielsen, H. (1991) Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin dependent diabetes mellitus. J. Clin. Invest. 88, 1282–1290.

    Article  CAS  Google Scholar 

  24. Walker, M., Fulcher, G. R., Catalano, C. (1989) Physiological levels of non-esterified fatty acids impair forearm glucose uptake in normal man. Diabetologia 32, 555A.

    Google Scholar 

  25. Zak, A., Zeman, M., Vitkova, D. (1994) Comparison of the effects of omega-3 polyunsaturated fatty acids and Olbetam (Acipimox) in the treatment of hypertriglyceridaemia. Cas. Lek. Cesk. 133, 755–758.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Department of Internal Medicine, University Medical School of Debrecen, P.O. Box 19, H-4012, Debrecen, Hungary

    G. Paragh, Z. Balogh, Judith Boda, P. Kovács, L. Kárpáti, J. Szabó &  A. Leövey

Authors
  1. G. Paragh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Balogh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Judith Boda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Kovács
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Kárpáti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Szabó
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Leövey
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dedicated to the memory of Professor Gábor Szabó.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paragh, G., Balogh, Z., Boda, J. et al. Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia. BIOLOGIA FUTURA 48, 359–367 (1997). https://doi.org/10.1007/BF03543206

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03543206

Keywords

Search

Navigation